Intriguingly, these small-molecule p53 activators have demonstrated selective toxicity for cancer cells versus normal cells [4,9], and may also induce reversible cell cycle arrest of normal cells to protect them from adverse effects of conventional chemotherapy [10]. The gene discussed is TP53; the disease is cancer.